Open up more treatment possibilities with Foundation Medicine.1-4

Foundation Medicine utilises hybrid capture-based next-generation sequencing to identify all four classes of genomic alterations, in a single report.1,5-9 

Tumour mutation burden (TMB) and microsatellite instability (MSI) status are also provided in the reports.5,7

Foundation Medicine applies its technology 
to three diagnostic profiles

  • Cancer type Solid tumours with access to good quality tissue samples5
  • Biopsy type FFPE
  • Identifies all four classes of genomic alterations Yes5
  • Determines TMB and/or MSI status Yes5
  • Cancer type Solid tumours with inadequate or insufficient tissue or where repeat biopsy is not feasible6
  • Biopsy type Peripheral whole blood
  • Identifies all four classes of genomic alterations Yes6
  • Determines TMB and/or MSI status No
  • Cancer type Haematological cancers and sarcomas7
  • Biopsy typ FFPE
  • Identifies all four classes of genomic alterations Yes7
  • Determines TMB and/or MSI status Yes7

FFPE: formalin-fixed paraffin embedded; MSI: microsatellite instability; TMB: tumour mutation burden.